Copyright  2017 Advantagene, Inc.  All rights reserved. Made by AFP.    Terms of use | Privacy policy

Stephen Rocamboli, Chief Business Officer

Stephen Rocamboli, Chief Business Officer.  Mr. Rocamboli is an experienced business and legal executive with a record of adding significant value for investors and companies in the life sciences arena.  In his role, Mr. Rocamboli helps direct our corporate strategy, leads our corporate finance activities and strategic partnering transactions, manages our legal affairs, and drives certain operational initiatives.  He also serves as our corporate secretary.  


Mr. Rocamboli honed his skills for nearly a decade as an integral member of a small team of executives at Paramount BioCapital that completed nearly $1 Billion in private financing transactions (debt and equity), launched and operated several investment funds with collective assets in excess of $1 Billion, and founded over 20 life science companies, many of which are publicly traded or have been sold, including ZioPharm Oncology (ZIOP), Chelsea Therapeutics International (acquired by Lundbeck), Cougar Biotechnology (acquired by J&J), Javelin Pharmaceuticals (acquired by Hospira), Velcera (acquired by Perrigo), and Cutanea Life Sciences (acquired by Maruho). Ultimately becoming Senior Managing Director & General Counsel at Paramount, Mr. Rocamboli’s expertise includes M&A, strategic partnering and licensing, and corporate finance. Mr. Rocamboli also has significant development stage pharmaceutical company leadership and operations experience.  Immediately prior to joining Advantagene, Mr. Rocamboli worked as a strategic consultant and legal counsel to life science entrepreneurs, companies and investors throughout the world. Mr. Rocamboli has been a member of the board of directors of numerous public and private companies and is currently a member of the board of directors of Cortice BioSciences (New York, NY) and Androvia Life Sciences (New York, NY) and was a member of the board of directors of Foresight Therapeutics until its sale to Shire Pharmaceuticals in 2015.

Mr. Rocamboli is a graduate of the State University of New York at Albany (B.A) and Fordham University School of Law (J.D).